FiercePharma10d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
GSK’s Blockbuster Vaccine Sales Plummet After US Troubles
Sales GSK Plc’s leading vaccines sank in the third quarter after the British drugmaker was hit by limited access to the shots ...
STAT10d
Sales of GSK’s RSV vaccine down dramatically from last year
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
The Pharma Letter3d
GSK’s Arexvy receives expanded approval in Canada
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
BioPharma Dive10d
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK lowers vaccine sales forecast as weak demand for RSV jab Arexvy takes toll
GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...
GSK PLC (GSK) Q3 2024 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...
GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...